← All trials
NCT06817421
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 30, 2025
- Primary completion
- Dec 31, 2027
- Completion date
- Feb 28, 2029
- First posted
- Feb 10, 2025
- Last posted
- Feb 11, 2025
- Enrollment
- 264
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Menzies School of Health ResearchLead sponsor
- University of Western AustraliaCollaborator
- University of EdinburghCollaborator
- Menzies School of Health ResearchSponsor investigator
- Murdoch UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.